Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

Simoctocog alfa (human-cl rhFVIII, Nuwiq®) is a 4th generation recombinant FVIII (rFVIII), without chemical modification or fusion with any other protein/fragment. Nuwiq® is produced in a human embryonic kidney cell line (HEK293F), which ensures human-specific post-translational protein processing....

Full description

Bibliographic Details
Main Authors: Toshko Lissitchkov, Anna Klukowska, John Pasi, Craig M. Kessler, Robert Klamroth, Raina J. Liesner, Larisa Belyanskaya, Olaf Walter, Sigurd Knaub, Johann Bichler, Martina Jansen, Johannes Oldenburg
Format: Article
Language:English
Published: SAGE Publishing 2019-06-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/2040620719858471

Internet

https://doi.org/10.1177/2040620719858471

Similar Items